Highlights:
MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ -- Incannex Healthcare Limited (Nasdaq:IXHL) (ASX:IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has engaged Curia Global, Inc. ('Curia') to further develop and manufacture GMP-grade IHL-216A, Incannex's proprietary inhaled drug product for the treatment of concussion and traumatic brain injury ('TBI').
Read more at prnewswire.com